TY - JOUR
T1 - Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression
T2 - A randomized 48-week study
AU - Llibre, Josep M.
AU - Buzón, Maria J.
AU - Massanella, Marta
AU - Esteve, Anna
AU - Dahl, Viktor
AU - Puertas, Maria C.
AU - Domingo, Pere
AU - Gatell, Josep M.
AU - Larrouse, Maria
AU - Mar, Gutierrez
AU - Palmer, Sarah
AU - Stevenson, Mario
AU - Blanco, Julià
AU - Martinez-Picado, Javier
AU - Clotet, Bonaventura
PY - 2012
Y1 - 2012
N2 - Background: Residual viraemia is a major obstacle to HIV-1 eradication in subjects receiving HAART. The intensification with raltegravir could impact latent reservoirs and might lead to a reduction of plasma HIV-1 viraemia (viral load [VL]), complementary DNA intermediates and immune activation. Methods: This was a prospective, open-label, randomized study comprising 69 individuals on suppressive HAART randomly assigned 2:1 to add raltegravir during 48 weeks. Results: Total and integrated HIV-1 DNA, and ultrasensitive VL remained stable despite intensification. There was a significant increase in episomal HIV DNA at weeks 2-4 in the raltegravir group returning to baseline levels at week 48. Median CD4 + T-cell counts increased 124 and 80 cells/μl in the intensified and control groups after 48 weeks (P=0.005 and P=0.027, respectively), without significant differences between groups. No major changes were observed in activation of CD4 + T-cells. Conversely, raltegravir intensification significantly reduced activation of CD8 + T-cells at week 48 (HLA-DR +CD38 +, P=0.005), especially in the memory compartment (CD38 + of CD8 +CD45RO +, P<0.0001). Linear mix models also depicted a larger decrease in CD8 + T-cell activation in the intensification group (P=0.036 and P=0.010, respectively). Raltegravir intensification was not associated to any particular adverse event. Conclusions: Intensification of HAART with raltegravir during 48 weeks was safe and associated with a significant decrease in CD8 + T-cell activation, and a transient increase of episomal HIV-1 DNA. However, raltegravir did not significantly contribute to changes in CD4 + T-cell counts, ultrasensitive VL, and total and integrated HIV-1 DNA. These findings suggest that raltegravir impacts residual HIV-1 replication and support new strategies to impair HIV-1 persistence.
AB - Background: Residual viraemia is a major obstacle to HIV-1 eradication in subjects receiving HAART. The intensification with raltegravir could impact latent reservoirs and might lead to a reduction of plasma HIV-1 viraemia (viral load [VL]), complementary DNA intermediates and immune activation. Methods: This was a prospective, open-label, randomized study comprising 69 individuals on suppressive HAART randomly assigned 2:1 to add raltegravir during 48 weeks. Results: Total and integrated HIV-1 DNA, and ultrasensitive VL remained stable despite intensification. There was a significant increase in episomal HIV DNA at weeks 2-4 in the raltegravir group returning to baseline levels at week 48. Median CD4 + T-cell counts increased 124 and 80 cells/μl in the intensified and control groups after 48 weeks (P=0.005 and P=0.027, respectively), without significant differences between groups. No major changes were observed in activation of CD4 + T-cells. Conversely, raltegravir intensification significantly reduced activation of CD8 + T-cells at week 48 (HLA-DR +CD38 +, P=0.005), especially in the memory compartment (CD38 + of CD8 +CD45RO +, P<0.0001). Linear mix models also depicted a larger decrease in CD8 + T-cell activation in the intensification group (P=0.036 and P=0.010, respectively). Raltegravir intensification was not associated to any particular adverse event. Conclusions: Intensification of HAART with raltegravir during 48 weeks was safe and associated with a significant decrease in CD8 + T-cell activation, and a transient increase of episomal HIV-1 DNA. However, raltegravir did not significantly contribute to changes in CD4 + T-cell counts, ultrasensitive VL, and total and integrated HIV-1 DNA. These findings suggest that raltegravir impacts residual HIV-1 replication and support new strategies to impair HIV-1 persistence.
UR - http://www.scopus.com/inward/record.url?scp=84860345691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860345691&partnerID=8YFLogxK
U2 - 10.3851/IMP1917
DO - 10.3851/IMP1917
M3 - Article
C2 - 22290239
AN - SCOPUS:84860345691
VL - 17
SP - 355
EP - 364
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 2
ER -